| (Values in U.S. Thousands) | Jun, 2026 | Mar, 2026 | Dec, 2025 | Sep, 2025 | Jun, 2025 |
| Sales | 3,780 | 3,050 | 85,090 | 90 | 20 |
| Sales Growth | +23.93% | -96.42% | +94,443.39% | +350.01% | +100.00% |
| Net Income | -72,940 | -68,760 | 19,400 | -56,880 | -54,660 |
| Net Income Growth | -6.08% | -454.43% | +134.11% | -4.06% | -13.95% |
4D Molecular Therapeutics Inc (FDMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
4D Molecular Therapeutics Inc. is a clinical-stage gene therapy company which develops product candidates using its targeted and evolved adeno-associated viruses vectors. It offers a portfolio of gene therapy product candidates focusing on the ophthalmology, cardiology and pulmonology therapeutic areas. 4D Molecular Therapeutics Inc. is based in Emeryville, California.
Fiscal Year End Date: 12/31